Toll Free: 1-888-928-9744

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 73 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2016', provides an overview of the Hyperphosphatemia In Chronic Kidney Disease pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease
- The report reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hyperphosphatemia In Chronic Kidney Disease therapeutics and enlists all their major and minor projects
- The report assesses Hyperphosphatemia In Chronic Kidney Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hyperphosphatemia In Chronic Kidney Disease Overview 7 Therapeutics Development 8 Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview 8 Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis 9 Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies 10 Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 11 Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies 15 Hyperphosphatemia In Chronic Kidney Disease - Products under Investigation by Universities/Institutes 16 Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development 17 3SBio Inc. 17 Ardelyx, Inc. 18 Daiichi Sankyo Company, Limited 19 Medice Arzneimittel Putter GmbH & Co. KG 20 OPKO Health, Inc. 21 Panion & Bf Biotech Inc 22 Shield Therapeutics Plc 23 Spectrum Pharmaceuticals, Inc. 24 Toray Industries, Inc. 25 Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 32 Drug Profiles 34 DS-2330 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 fermagate - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ferric citrate - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 JPH-101 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 niacinamide - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 PDX-004 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 PT-20 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 RDX-002 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 sevelamer carbonate - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Small Molecules to Target Phosphate for Hyperphosphatemia - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 SPI-014 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 tenapanor hydrochloride - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 TRK-390 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 VS-501 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects 59 Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products 60 Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones 61 Featured News & Press Releases 61 Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease 61 May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia 62 Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology 62 Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 63 Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 64 Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate 65 Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 65 Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 66 Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting 67 Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex 67 Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency 68 Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan 68 Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application 69 Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013 69 Oct 08, 2013: Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex New Drug Application 70 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2016 8 Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by 3SBio Inc., H1 2016 17 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx, Inc., H1 2016 18 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 19 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H1 2016 20 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health, Inc., H1 2016 21 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc, H1 2016 22 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H1 2016 23 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 24 Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Toray Industries, Inc., H1 2016 25 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Stage and Target, H1 2016 28 Number of Products by Stage and Mechanism of Action, H1 2016 30 Number of Products by Stage and Route of Administration, H1 2016 31 Number of Products by Stage and Molecule Type, H1 2016 33 Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H1 2016 59 Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H1 2016 60


List of Figures
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2016 8 Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 26 Number of Products by Top 10 Targets, H1 2016 27 Number of Products by Stage and Top 10 Targets, H1 2016 27 Number of Products by Mechanism of Actions, H1 2016 29 Number of Products by Stage and Mechanism of Actions, H1 2016 29 Number of Products by Stage and Routes of Administration, H1 2016 31 Number of Products by Molecule Types, H1 2016 32 Number of Products by Stage and Molecule Types, H1 2016 32

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify